T1DM is characterized by low bone mass and impaired bone formation due to insulin deficiency, reduced insulin-like growth factor 1 (IGF-1) signaling, and accumulation of advanced glycation end-products (AGEs) that deteriorate bone matrix quality. The gene discussed is IGF1; the disease is type 1 diabetes mellitus.